Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Longitudinal performance of the bronchiectasis severity index (BSI) in patients on regular intravenous (IV) antibiotic therapy for bronchiectasis

Prasad Palani Velu, Pallavi Bedi, Kim Turnbull, Adam T. Hill
European Respiratory Journal 2016 48: PA2554; DOI: 10.1183/13993003.congress-2016.PA2554
Prasad Palani Velu
1Department of Respiratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pallavi Bedi
2MRC Centre for Inflammation Research, Queen's Medical Research Institute, Edinburgh, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim Turnbull
1Department of Respiratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam T. Hill
1Department of Respiratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
2MRC Centre for Inflammation Research, Queen's Medical Research Institute, Edinburgh, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Introduction: – The Bronchiectasis Severity Index (BSI) is a multi-dimensional tool that identifies risk of future mortality, admissions to hospital and exacerbations in patients with bronchiectasis. We aimed to investigate if the BSI reflects changes in the severity of bronchiectasis over time.

Methods: – Retrospective cohort study of patients with bronchiectasis on long-term intravenous (IV) antibiotics. Demographic data and clinical parameters required for calculation of BSI were gathered.

Results: – Fifteen patients on regular IV antibiotics were assessed over 1 year. Median age was 66 and 40% were male. Median BSI rose from 11 (IQR 9 – 13) to 12 (10.5 – 14.5)(p=0.12, Wilcoxon-Signed Rank test). BSI remained static in 1 (6.7%), decreased in 3 (20%) and increased in 11 (73.3%) patients. Improvements in BSI were due to reduction in the number of exacerbations and hospital admissions (2, 13.3%) or improvement in predicted FEV1 (1, 6.7%). Worsening BSI was attributable to decline in predicted FEV1 (3, 20%), admissions to hospital (2, 13.3%), Pseudomonas colonisation (2, 13.3%), colonisation with other organisms (1, 6.7%), increased number of exacerbations (1, 6.7%) increasing age (1, 6.7%) and increasing breathlessness (1, 6.7%).

Conclusion: – The BSI is sensitive enough to detect changes in disease severity, particularly in hospital admissions, number of exacerbations, predicted FEV1 and bacterial colonisation. It thus has a potential role as a tool to monitor response to interventions in bronchiectasis. Further work with longer follow-up and a larger cohort of patients may demonstrate a statistically significant change in BSI.

  • Bronchiectasis
  • Monitoring
  • Treatments
  • Copyright ©the authors 2016
Previous
Back to top
Vol 48 Issue suppl 60 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Longitudinal performance of the bronchiectasis severity index (BSI) in patients on regular intravenous (IV) antibiotic therapy for bronchiectasis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Longitudinal performance of the bronchiectasis severity index (BSI) in patients on regular intravenous (IV) antibiotic therapy for bronchiectasis
Prasad Palani Velu, Pallavi Bedi, Kim Turnbull, Adam T. Hill
European Respiratory Journal Sep 2016, 48 (suppl 60) PA2554; DOI: 10.1183/13993003.congress-2016.PA2554

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Longitudinal performance of the bronchiectasis severity index (BSI) in patients on regular intravenous (IV) antibiotic therapy for bronchiectasis
Prasad Palani Velu, Pallavi Bedi, Kim Turnbull, Adam T. Hill
European Respiratory Journal Sep 2016, 48 (suppl 60) PA2554; DOI: 10.1183/13993003.congress-2016.PA2554
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Abortive replication and reactivation in vitro respiratory syncytial virus (RSV) infection in palivizumab-treated HeLa cells
  • Impact of nasopharyngeal pneumococcal colonization on dendritic cell-dependent protective immunity against invasive pneumococcal disease in mice
  • Risk factors and treatment outcomes in patients with chronic pulmonary aspergillosis
Show more 10.1 Respiratory Infections

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society